Nusinersen, sold under the brand name Spinraza, is the drug that has fundamentally changed the trajectory of spinal muscular atrophy, a rare and often devastating genetic disorder that progressively weakens muscles and, in its most severe forms, can be fatal in early childhood. Approved by the FDA in December 2016, Spinraza became the first treatment ever approved for SMA, and its arrival marked a turning point for thousands of patients and families who previously had no disease-modifying therapy available. Since then, additional treatments have followed, but Spinraza remains a cornerstone option, particularly for patients diagnosed later in life or those who may not be candidates for newer gene therapies.
Consider the case of a child diagnosed with Type 1 SMA, the most severe form, where infants historically rarely survived past their second birthday without ventilator support. Clinical trials for Spinraza showed that treated infants achieved motor milestones, such as sitting independently, that untreated children with the same diagnosis almost never reached. For families facing this diagnosis, the existence of a viable treatment has shifted conversations from palliative care to cautious optimism. This article explores how Spinraza works, what other treatments have entered the field, the real-world challenges patients face in accessing these therapies, and what the future may hold for SMA care, particularly as it intersects with broader neurological health.
Table of Contents
- How Is Spinraza Changing the Lives of Spinal Muscular Atrophy Patients?
- Understanding How SMA Treatments Work at the Genetic Level
- The Expanding Landscape of SMA Therapies Beyond Spinraza
- Navigating the Cost and Access Challenges of SMA Treatment
- Long-Term Outcomes and the Limits of Current Knowledge
- The Critical Role of Newborn Screening in SMA Outcomes
- What the Future Holds for SMA Treatment and Neurological Research
- Conclusion
- Frequently Asked Questions
How Is Spinraza Changing the Lives of Spinal Muscular Atrophy Patients?
Spinal muscular atrophy is caused by mutations in the SMN1 gene, which is responsible for producing survival motor neuron protein. Without adequate levels of this protein, motor neurons in the spinal cord degenerate, leading to progressive muscle weakness and atrophy. Spinraza works by targeting a related gene, SMN2, which normally produces only a small amount of functional SMN protein. The drug is an antisense oligonucleotide, a synthetic strand of modified RNA, that essentially corrects the way SMN2 is read by cellular machinery, coaxing it into producing more of the full-length, functional protein that patients desperately need. The clinical impact has been significant. In the pivotal ENDEAR trial, which studied infants with Type 1 SMA, a substantially higher proportion of Spinraza-treated infants achieved motor milestones compared to those receiving sham procedures. Some children who would have been expected to never sit unsupported were pulling to stand.
However, outcomes vary considerably depending on when treatment begins. Patients treated before symptom onset, often identified through newborn screening programs, tend to show the most dramatic improvements. Those who begin treatment after significant motor neuron loss has already occurred may stabilize or see more modest gains, which underscores a critical reality: the drug can slow or alter disease progression, but it cannot fully reverse damage that has already taken place. For older children and adults with milder SMA types, such as Type 2 or Type 3, the picture is more nuanced. Many report meaningful improvements in endurance, hand function, or respiratory capacity, though these gains can be subtle and are sometimes difficult to capture on standard motor function scales. The lived experience of being able to hold a fork more steadily or type for longer periods matters enormously to patients, even when it does not register as a dramatic clinical endpoint.
Understanding How SMA Treatments Work at the Genetic Level
To appreciate why SMA therapies represent such a breakthrough, it helps to understand the genetic underpinnings of the disease. Nearly all humans carry both SMN1 and SMN2 genes, but patients with SMA have deletions or mutations in SMN1 that render it nonfunctional. The SMN2 gene serves as a backup, but due to a single nucleotide difference, roughly 90 percent of the protein it produces is truncated and quickly degraded. The small amount of functional protein from SMN2 is not enough to sustain motor neurons over time, which is why the disease is progressive. Spinraza’s mechanism of modifying SMN2 splicing is elegant but comes with practical limitations.
The drug does not cross the blood-brain barrier effectively when given systemically, so it must be administered via intrathecal injection, meaning it is delivered directly into the spinal fluid through a lumbar puncture. Patients require loading doses followed by maintenance injections approximately every four months, indefinitely. For individuals with severe scoliosis, spinal fusion hardware, or other anatomical complications common in the SMA population, these injections can be technically challenging and sometimes require imaging guidance or sedation. However, if a patient has significant spinal hardware or anatomical barriers that make lumbar puncture unsafe or impractical, Spinraza may not be a viable long-term option. This is one area where alternative treatments, such as the oral drug risdiplam or the gene therapy onasemnogene abeparvovec, may offer advantages. Each therapy has a distinct delivery method, mechanism, and patient profile, which means treatment decisions are rarely one-size-fits-all.
The Expanding Landscape of SMA Therapies Beyond Spinraza
Spinraza opened the door, but it is no longer the only option. Onasemnogene abeparvovec, marketed as Zolgensma, received FDA approval in 2019 as a one-time intravenous gene therapy for children under two years of age with SMA. It works by delivering a functional copy of the SMN1 gene using an adeno-associated virus vector, essentially giving the body the genetic instructions it was missing. In clinical studies, treated infants showed remarkable improvements, with some achieving milestones like independent walking that would be extraordinary for children with SMA. Risdiplam, sold as Evrysdi, was approved in 2020 and works similarly to Spinraza in that it modifies SMN2 splicing, but it is taken orally as a daily liquid.
This represented a significant practical advance for patients who found repeated spinal injections burdensome. Risdiplam is approved for patients two months of age and older, making it accessible across a wide age range. The availability of three distinct treatments has created genuine choices for families and clinicians, but it has also introduced complexity. For a newborn identified through screening, the question of whether to pursue gene therapy, start an SMN2 splicing modifier, or even combine approaches is an evolving clinical discussion. Real-world registries and long-term follow-up data are still being gathered, and as of recent reports, there is no definitive consensus on which therapy is optimal for every patient subgroup. Decisions often hinge on factors like age, disease severity, insurance coverage, and the treating center’s experience.
Navigating the Cost and Access Challenges of SMA Treatment
The financial reality of SMA treatment is staggering and cannot be separated from any honest discussion of these therapies. Spinraza has historically carried an annual cost in the hundreds of thousands of dollars, with the first year of loading doses being particularly expensive. Zolgensma made headlines as one of the most expensive single treatments in medical history, with a list price that has been reported in the millions of dollars. Risdiplam, while generally less expensive on an annual basis than Spinraza, still represents a significant ongoing cost. For families, the practical experience of accessing these treatments often involves navigating insurance prior authorizations, appeals, and sometimes legal advocacy.
Manufacturer patient assistance programs exist, and in some cases, nonprofit organizations help bridge gaps, but the process can be exhausting and time-consuming, particularly for families already managing the daily demands of caring for a child or adult with a serious disability. In countries without robust insurance systems or where these drugs have not yet been approved or reimbursed, access remains severely limited. The tradeoff between a one-time gene therapy and ongoing treatments is worth considering carefully. Zolgensma’s single administration is appealing, but its long-term durability beyond several years is still being studied, and there are open questions about whether patients may eventually need supplemental therapy. Spinraza and risdiplam require indefinite treatment, but they also allow for dose adjustments and have longer track records in certain populations. There is no clearly superior financial or clinical path for every patient, and the decision often involves weighing known costs against uncertain long-term outcomes.
Long-Term Outcomes and the Limits of Current Knowledge
One of the most important caveats in the SMA treatment landscape is that long-term data remain limited. Spinraza has been in clinical use for less than a decade, Zolgensma for an even shorter period, and risdiplam shorter still. While early and medium-term results have been encouraging, the durability of these treatments over a full lifespan is genuinely unknown. Patients and families should be aware that the optimistic narratives, while grounded in real clinical evidence, are based on a relatively brief window of observation. There are also patients for whom treatment has not delivered the hoped-for results. Late-treated individuals with significant motor neuron loss may stabilize but not recover meaningful function.
Some patients experience side effects, including the risk of liver toxicity with Zolgensma or the discomfort and potential complications of repeated lumbar punctures with Spinraza. Post-marketing surveillance has identified rare but serious adverse events that were not fully captured in clinical trials, which is a normal part of any new therapy’s maturation but is important for patients to understand. A particular concern in the SMA community is the gap between clinical trial populations and real-world patients. Trials often have strict inclusion criteria, enrolling relatively young, otherwise healthy patients. The adult SMA population, many of whom have lived with the disease for decades and have complex medical histories including respiratory compromise and orthopedic complications, is less well-represented in the evidence base. Their treatment responses may differ from what trials have shown, and clinicians are still learning how to optimize therapy for this group.
The Critical Role of Newborn Screening in SMA Outcomes
One of the most consequential developments alongside the arrival of SMA treatments has been the expansion of newborn screening programs. When SMA is identified before symptoms appear, treatment can begin in the pre-symptomatic window, and outcomes in this group have been dramatically better than in children treated after symptom onset. In some cases, pre-symptomatically treated infants have developed motor skills within normal ranges, an outcome that would have been almost unthinkable before 2016.
As of recent reports, a growing number of states in the U.S. and countries worldwide have added SMA to their newborn screening panels, though adoption is not universal. Families in regions without routine SMA screening may not receive a diagnosis until symptoms become apparent, which can mean months or years of irreversible motor neuron loss. Advocacy organizations have been instrumental in pushing for broader screening adoption, and this effort represents one of the clearest examples of how early detection paired with effective treatment can fundamentally alter the course of a genetic disease.
What the Future Holds for SMA Treatment and Neurological Research
The progress in SMA has implications that extend beyond the disease itself. The success of antisense oligonucleotide therapy and gene therapy in SMA has energized research into similar approaches for other neurodegenerative and neurological conditions, including amyotrophic lateral sclerosis, Huntington’s disease, and certain forms of dementia. The principle that targeted genetic intervention can modify the course of a neurodegenerative disease has broad relevance, and lessons learned from the SMA experience, both scientific and logistical, are informing these efforts.
Looking ahead, combination therapy approaches, next-generation compounds with improved delivery or durability, and therapies targeting muscle and other tissues beyond motor neurons are all areas of active investigation. For the SMA community, the hope is not just survival but improved quality of life across the full lifespan. The story is still being written, and while the early chapters have been remarkably promising, honest uncertainty about long-term outcomes remains an important part of the conversation.
Conclusion
The arrival of Spinraza, followed by Zolgensma and Evrysdi, has transformed spinal muscular atrophy from a diagnosis with limited options into a condition with genuine therapeutic possibilities. Patients who would have faced progressive decline now have treatments that can stabilize or improve their condition, particularly when therapy begins early. The expansion of newborn screening has amplified these gains by enabling pre-symptomatic treatment, and the SMA experience has become a model for precision medicine in neurological disease.
At the same time, significant challenges remain. The cost of treatment is extraordinary, access is uneven across geographies and insurance systems, and long-term outcomes are still being defined. Patients and families navigating an SMA diagnosis should work closely with neuromuscular specialists, explore all available treatment options and support programs, and maintain realistic expectations grounded in the best available evidence. The progress is real and meaningful, but the journey toward optimal care for every SMA patient is far from complete.
Frequently Asked Questions
What is the most common drug used for spinal muscular atrophy?
Nusinersen (Spinraza) was the first FDA-approved treatment for SMA and remains widely used, particularly for patients across all age groups. Risdiplam (Evrysdi) and onasemnogene abeparvovec (Zolgensma) are also approved options, with the choice depending on patient age, disease severity, and practical factors like administration route.
Can SMA treatments cure the disease?
Current treatments can significantly slow progression and, in some cases, allow patients to gain motor function they would not have achieved otherwise. However, none of the available therapies is considered a definitive cure, and most require ongoing treatment or monitoring. Gene therapy offers a one-time approach, but its long-term durability is still under study.
Is spinal muscular atrophy related to dementia or other brain conditions?
SMA primarily affects motor neurons in the spinal cord, not the brain regions associated with cognition or memory. Patients with SMA typically have normal or above-average intelligence. However, the genetic and therapeutic principles behind SMA treatments are informing research into other neurodegenerative conditions, including some that do affect cognition.
How is SMA diagnosed in newborns?
SMA can be detected through newborn screening programs that test for deletions in the SMN1 gene using a blood spot collected shortly after birth. Not all regions offer this screening, so in some cases, diagnosis occurs only after a child begins showing symptoms such as muscle weakness or difficulty reaching motor milestones.
What are the side effects of Spinraza?
The most commonly reported side effects include respiratory infections, constipation, and headache. The intrathecal injection procedure itself carries risks associated with lumbar puncture, including post-procedural headache and, rarely, infection. Patients with spinal abnormalities may face additional procedural challenges.
Are there age limits for SMA treatment?
Zolgensma is approved for children under two years of age. Spinraza and risdiplam are approved for broader age ranges, including adults. However, the degree of benefit may vary based on disease duration and existing motor neuron loss, and treatment decisions for older patients require careful discussion with a specialist.
